Successful treatment of scleromyxedema using thalidomide [49]

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 10, 2006, Pages 1396-1397

  Thyssen, J P ^a   Zachariae, C ^a   Menne T ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; THALIDOMIDE;

ADULT; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCLEROMYXEDEMA; TREATMENT DURATION; TREATMENT OUTCOME;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SCLEROMYXEDEMA; THALIDOMIDE;

EID: 33750370435     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01761.x     Document Type: Letter

References (4)

1. Caradonna S, Jacobe H. Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol 2004; 140: 277-280.
2. Sansbury JC, Cocuroccia B, Jorizzo JL et al. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 2004; 51: 126-131.
3. Bastuji-Garin S, Ochonisky S, Bouche P et al. Incidence and risk factors for thalidomide neuropathy: A prospective study of 135 dermatologic patients. J Invest Dermatol 2002; 119: 1020-1026.
4. Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol 1995; 33: 37-43.